News for NVOS Stock

Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program Novo Integrated Sciences’ Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program Novo Integrated Sciences Receives Confirmation of Ready, Willing and Able (RWA) Issued by HSBC for SBLC Leasing and Monetizing Program Novo Integrated Sciences Reports Fiscal Year 2024 Second Quarter Financial Results Novo Integrated Sciences Closes on $6,210,000 Securities Purchase Agreement Novo Integrated Sciences Provides Update on Certain Current Actions and Events Novo Integrated Sciences Subsidiary, Clinical Consultants International, Signs Agreement with Futura Surgicare Pvt Ltd. Novo Integrated Sciences Receives Limited Waiver to Securities Purchase Agreement for $70,000,000 Promissory Note Novo Integrated Sciences Appoints New President Novo Integrated Sciences Reports Fiscal Year 2024 First Quarter Financial Results Blacksheep Trust Files Partial Assignment of $1 Billion Dollar Gold Backed Bond to Novo Integrated Sciences Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results Novo Integrated Sciences Signs Master Collaboration Agreement with Psychocare Health Pvt. Ltd. India Novo Integrated Sciences’ Purchase and Sale Agreement to Acquire Ophir Collection Receives Court Approval Novo Integrated Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement Novo Integrated Sciences Announces Reverse Stock Split Novo Integrated Sciences Advised Receipt of Proceeds of RC Consulting Promissory Note Expected in 3-5 Business Days Novo Integrated Sciences Announces Issuance of Underlying One Billion Dollar Gold Backed Bond Novo Integrated Sciences’ Board of Directors Approves $5 Million Stock Repurchase Program Novo Integrated Sciences Provides Update on Certain Current Events Novo Integrated Sciences Signs Master Collateral Transfer Agreement Novo Integrated Sciences Provides Update on Certain Current Actions and Events Novo Integrated Sciences’ IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health Novo Integrated Sciences Provides Update on Potential Share Repurchase Program Novo Integrated Sciences Receives Underwriter Clearance Notice for $70,000,000 Coupon Acenzia Selected to join Team Canada Trade Mission to India Novo Integrated Sciences’ IoNovo Iodine Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health Novo Integrated Sciences Provides Update on Certain Current Actions and Events Novo Integrated Sciences and Farm 7 Group Announce Joint Venture for Kenya Cooperative Agricultural Project Novo Integrated Sciences Reports Fiscal Year 2023 Third Quarter Financial Results Novo Integrated Sciences Receives $40,000,000 Commitment to Develop Eldercare Facilities in Canada Novo Integrated Sciences Reports Fiscal Year 2023 Second Quarter Financial Results Novo Integrated Sciences Reports Fiscal Year 2023 First Quarter Financial Results Novo Integrated Sciences Signs Agreements for an Unsecured, Non-dilutive Debt Instrument with a Principal Sum of $70,000,000 Novo Integrated Sciences Reports Fiscal Full Year 2022 Financial Results Novo Integrated Sciences Provides Update on Certain Current Actions and Events Novo Integrated Sciences Announces Receipt of Notice from Nasdaq Novo Integrated Sciences Provides Update on Certain Current Actions and Events Novo Integrated Sciences Announces Receipt of Notice from Nasdaq Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc. Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Smart Healthcare Solution Provider, TiaTech USA Inc. Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Sales & Consulting Agreement with Tranquility Lifestyle Solutions Novo Integrated Sciences, Inc. Announces Pricing of $2.0 Million Public Offering Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Services Agreement with Information Technology Company, Softhread Embracing Technology and Innovation “Key” to Easing Healthcare Crisis Novo Integrated Sciences Reports Record Revenue of $13.8 million in Fiscal 2022 Third Quarter Novo Integrated Sciences Announces Preliminary Revenue Range for Fiscal 2022 Third Quarter Novo Integrated Sciences’ Chairman and CEO to Present at the AAPI CEO Forum on the Future of Healthcare: Technology, Transformation and Beyond Novo Integrated Sciences’ Chief Medical Officer, Dr. Joseph M. Chalil, Selected as Top Physician of the Year by IAOTP Novo Integrated Sciences Reports Fiscal 2022 Second Quarter Financial Results Novo Integrated Sciences Completes Acquisition of Clinical Consultants International LLC Novo Integrated Sciences Signs Memorandum of Understanding with Boditech Med, a Global Point-of-Care Testing Leader, to Market and Distribute in North America Novo Integrated Sciences’ PRO-DIP® Issued U.S. Patent for Oral Pouch Delivery System Technology Novo Integrated Sciences Enters into Purchase Agreement to Acquire Clinical Consultants International LLC Novo Integrated Sciences to Participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest Novo Integrated Sciences’ IoNovo Iodide Granted Natural Product Number (NPN) by Health Canada Novo Integrated Sciences’ IoNovo for Kids Pure Iodine Oral Spray Granted Natural Product Number (NPN) by Health Canada Novo Integrated Sciences Reports First Quarter Financial Results Novo Integrated Sciences Announces the Signing of a Master Facility License Agreement with LA Fitness in Canada Novo Integrated Sciences Granted Natural Product Number (NPN) by Health Canada for IoNovo Iodine Branded Product Novo Integrated Sciences Reports Fiscal Full Year 2021 Financial Results Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient Novo Integrated Sciences’ subsidiary, Novo Healthnet Limited, and EK-Tech Solutions Announce Joint Venture for Enhanced Telehealth Platform Novo Integrated Sciences to Present at the Benzinga Virtual Global Healthcare Small Cap Conference on September 30th Novo Integrated Sciences Signs LOIs to Acquire Seven Pharmacies in the United States Novo Integrated Sciences Announces Third Quarter 2021 Financial Results Novo Integrated Sciences Appoints Dr. Indrajit (Indra) Sinha Ph.D. as Chief Science Officer Novo Integrated Sciences and Novo Healthnet Limited Complete Acquisition of Acenzia Novo Integrated Sciences Enters into Share Exchange Agreement to Acquire Acenzia Inc. Novo Integrated Sciences Completes Acquisition of PRO-DIP, LLC Novo Integrated Sciences Enters into Share Exchange Agreement to Acquire PRO-DIP, LLC Novo Integrated Sciences Announces Formation of Medical Advisory Board Novo Integrated Sciences Announces Closing of $8 Million Registered Direct Offering Novo Integrated Sciences Announces Second Quarter 2021 Financial Results Novo Integrated Sciences Announces Pricing of $8.0 Million Registered Direct Offering Novo Integrated Sciences Announces Preliminary Revenue and Financial Results of Second Quarter Fiscal Year ‘21 Novo Integrated Sciences to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, March 17-19, 2021 Novo Integrated Sciences Announces New Executive Hires for Novo Healthnet Limited Novo Integrated Sciences Announces Uplist to The Nasdaq Capital Market Novo Integrated Sciences Announces New President of Novo Healthnet Limited Novo Integrated Sciences Effects Reverse Stock Split in Connection with Nasdaq Capital Market Listing Application Novo Integrated Sciences Announces Three New Independent Directors Appointed to its Board of Directors and Formation of an Audit Committee